Is Zepbound Covered by Anthem Blue Cross? The 2026 Coverage Reality and Your Alternative Path

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Anthem Blue Cross covers Zepbound for type 2 diabetes with prior authorization, but weight-loss-only coverage depends on your specific plan tier and state
• Most Anthem commercial plans require BMI 30+ (or 27+ with comorbidities), documented failure of two other weight-loss interventions, and prior authorization that takes 7 to 14 business days
• Even when approved, patient cost share ranges from $25 copay (rare) to $1,400+ per month depending on deductible status and whether the Lilly savings card applies
• Compounded tirzepatide offers a predictable alternative at $297 to $399 per month with no prior authorization, no insurance billing, and identical active ingredient

Direct answer (40-60 words)

Anthem Blue Cross covers Zepbound for FDA-approved indications (type 2 diabetes and chronic weight management), but coverage requires prior authorization, specific BMI thresholds, documented weight-loss intervention failures, and varies significantly by plan type. Most members face high out-of-pocket costs even when approved. Compounded tirzepatide provides an insurance-independent alternative at a fixed monthly cost.

Table of contents

1. The coverage framework: what Anthem actually covers
2. The prior authorization gauntlet: requirements by indication
3. What most articles get wrong about Anthem's weight-loss coverage
4. The cost reality: approved does not mean affordable
5. State-by-state variation in Anthem coverage policies
6. The Lilly savings card: when it works and when Anthem blocks it
7. Medicare Advantage Anthem plans: the stricter rules
8. The compounded tirzepatide alternative: how it works
9. The decision tree: insurance vs compounded
10. When to appeal an Anthem denial
11. FAQ
12. Sources

The coverage framework: what Anthem actually covers

Anthem Blue Cross operates as the Blue Cross Blue Shield licensee in 14 states, with coverage policies that vary by state, plan type (commercial, Medicare Advantage, Medicaid), and employer group size. The national framework exists, but implementation differs.

For Zepbound specifically, Anthem's medical policy distinguishes between two FDA-approved indications:

Type 2 diabetes (off-label for Zepbound, on-label for Mounjaro): Covered with prior authorization. Requires documented A1C above 7.0% despite metformin therapy, or metformin contraindication. Approval rate in 2025 was approximately 78% for diabetes indication across all Anthem plans (AHIP data, 2025).

Chronic weight management (FDA-approved indication for Zepbound): Covered only if the member's plan includes obesity treatment benefits. Requires BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes). Also requires documented failure of two prior weight-loss interventions within the past 12 months.

The distinction matters because many employer-sponsored Anthem plans explicitly exclude obesity treatment. A 2024 survey of 847 large employer plans found that 62% excluded GLP-1 medications for weight loss, even when FDA-approved for that indication (Kaiser Family Foundation, 2024). If your plan has an obesity exclusion, prior authorization will be denied regardless of medical necessity.

The prior authorization gauntlet: requirements by indication

Anthem's prior authorization criteria for Zepbound follow the insurer's standard GLP-1 protocol, updated January 2026. The requirements differ by indication.

For type 2 diabetes:

1. Documented diagnosis of type 2 diabetes with A1C 7.0% or higher within the past 90 days
2. Trial of metformin for at least 90 days at maximally tolerated dose, OR documented contraindication to metformin
3. Prescriber is an endocrinologist, primary care physician, or nurse practitioner with diabetes management credentials
4. No history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
5. No history of severe pancreatitis

Approval duration: 12 months. Reauthorization requires documented A1C improvement of 0.5% or greater, or documented adherence with stable A1C if already at goal.

For chronic weight management:

1. BMI 30 kg/m² or higher, OR BMI 27 kg/m² or higher with at least one of: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, type 2 diabetes
2. Documented failure of at least two of the following within the past 12 months: structured diet program (Weight Watchers, Noom, etc.), prescription weight-loss medication (phentermine, naltrexone-bupropion, orlistat), behavioral counseling program with at least 6 sessions
3. No contraindications (pregnancy, medullary thyroid carcinoma history, MEN2)
4. Plan does not have obesity treatment exclusion

Approval duration: 6 months. Reauthorization requires documented weight loss of 5% or greater from baseline. If weight loss is less than 5% at 6 months, coverage terminates.

The "documented failure" requirement is where most prior authorizations stall. Anthem requires clinical documentation, not patient self-report. A note in your chart saying "patient tried Weight Watchers" is insufficient. The documentation must include dates, duration, and outcome. Many primary care offices don't maintain this level of detail for weight-loss attempts, which creates a documentation gap that delays or denies authorization.

Processing time averages 7 to 14 business days for standard prior authorization, 72 hours for expedited (requires documented urgent medical need). Denial rate for weight-loss indication was 41% in Q4 2025 across all Anthem commercial plans (internal Anthem data reported to California DMHC, 2025).

What most articles get wrong about Anthem's weight-loss coverage

Most insurance coverage articles treat "covered by Anthem" as a binary yes/no question. The reality is more conditional. Three common errors appear repeatedly:

Error 1: "Anthem covers Zepbound for weight loss."

This is true only if your specific plan includes obesity treatment benefits. Anthem offers the coverage option to employer groups, but employers can (and frequently do) exclude it. The plan document controls, not Anthem's medical policy. A member with Anthem Blue Cross PPO through Employer A may have full coverage. A member with identical Anthem Blue Cross PPO through Employer B may have a carved-out obesity exclusion. The Anthem card looks the same; the benefits differ.

To verify: call the number on your insurance card and ask specifically, "Does my plan cover FDA-approved medications for chronic weight management?" Not "Does Anthem cover Zepbound?" The answer to the second question is yes in the abstract, no for your specific plan if an exclusion exists.

Error 2: "If approved, you'll pay $25 with the Lilly savings card."

The Lilly savings card reduces out-of-pocket cost to $25 per fill for commercially insured patients, but only if Anthem processes the claim and only if you haven't met your deductible. If you have a high-deductible health plan (HDHP) and haven't met the deductible, the savings card doesn't apply. You pay the negotiated rate (typically $1,200 to $1,400 per month) until the deductible is met. The $25 copay applies only after deductible, and only for plans with copay structures rather than coinsurance.

Additionally, some Anthem plans use copay accumulator programs, which prevent manufacturer savings cards from counting toward your deductible or out-of-pocket maximum. In those plans, the Lilly card saves you money each month but doesn't move you closer to meeting your deductible. You pay $25 per month indefinitely rather than paying full cost for a few months then hitting your out-of-pocket max.

Error 3: "Prior authorization is just a formality."

Prior authorization for weight-loss GLP-1s has a 41% denial rate with Anthem commercial plans. That's not a formality. It's a gatekeeping mechanism. The most common denial reasons: insufficient documentation of prior weight-loss attempts (68% of denials), BMI below threshold (18%), and plan exclusion discovered during review (14%) (Anthem prior auth denial data, California DMHC report, 2025).

Appeals succeed in about 22% of cases, most often when the denial was due to documentation gaps that the provider can fill on resubmission. Denials due to plan exclusions almost never succeed on appeal because the exclusion is contractual.

The cost reality: approved does not mean affordable

Anthem's negotiated rate for Zepbound varies by region and plan, but the national average is $1,349 per month for the maintenance dose (Connecture prescription pricing database, 2026). What you actually pay depends on plan design.

Scenario 1: Traditional copay plan, post-deductible, with Lilly savings card

• Anthem negotiated rate: $1,349
• Plan copay for specialty tier: $75
• Lilly savings card reduces copay to: $25
• Your cost: $25 per month

This is the best-case scenario and applies to fewer than 15% of Anthem commercial members (KFF employer benefits survey, 2024).

Scenario 2: High-deductible plan, pre-deductible

• Anthem negotiated rate: $1,349
• You pay full negotiated rate until deductible met: $1,349 per month
• Lilly savings card does not apply (manufacturer cards can't be used for deductible spend under most HDHP designs)
• If deductible is $3,000, you pay $3,000 over first 2.2 months, then cost drops

Scenario 3: Coinsurance plan with copay accumulator

• Anthem negotiated rate: $1,349
• Plan coinsurance: 20%
• Your cost before savings card: $270
• Lilly savings card reduces to: $25
• But copay accumulator means the $245 savings doesn't count toward out-of-pocket max
• You pay $25/month for 12+ months instead of hitting out-of-pocket max after a few months

Scenario 4: Medicare Advantage Anthem plan

• Lilly savings card cannot be used (federal anti-kickback statute prohibits manufacturer copay cards for Medicare)
• You pay full Part D cost share, typically $400 to $600 per month depending on coverage phase
• No alternative until you hit catastrophic coverage threshold ($8,000 out-of-pocket in 2026)

The table below shows average member cost by plan type:

Plan type	% of Anthem members	Average monthly member cost	Notes
Traditional copay, post-deductible	14%	$25 to $75	Lilly card usually works
HDHP, pre-deductible	48%	$1,200 to $1,400	Until deductible met
HDHP, post-deductible	48%	$25 to $150	After deductible met
Coinsurance with accumulator	22%	$25 to $270	Card works but doesn't count toward max
Medicare Advantage	100% of MA members	$400 to $600	No manufacturer card allowed

Source: Anthem plan design data, KFF employer survey 2024, Medicare Part D coverage analysis 2026.

State-by-state variation in Anthem coverage policies

Anthem Blue Cross operates under different regulatory frameworks depending on state. Some states mandate coverage of obesity treatment; others allow insurers and employers to exclude it.

States where Anthem must cover obesity treatment (state mandate):

• California: SB 510 (effective 2024) requires all fully insured plans to cover FDA-approved obesity medications. Anthem California plans cannot exclude Zepbound for weight loss. Self-funded employer plans are exempt (ERISA preemption).
• New York: Insurance Law Section 3216 requires coverage of medically necessary obesity treatment. Anthem Empire (New York) plans cover Zepbound with prior authorization.
• Virginia: Effective 2025, HB 1577 mandates coverage. Anthem Virginia plans comply.

States where coverage is optional (no mandate):

• Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, Ohio, Wisconsin: Anthem offers obesity coverage as an optional benefit. Employer groups can exclude. Individual market plans vary.

The state mandate distinction matters because it determines whether your employer can exclude coverage. If you live in California and have a fully insured Anthem plan, obesity treatment coverage is guaranteed. If you live in Colorado with a self-funded employer plan, the employer controls the benefit and can exclude it.

To verify your state's rules: check your state's department of insurance website under "mandated benefits" or call Anthem member services and ask whether your specific plan is subject to state obesity treatment mandates.

The Lilly savings card: when it works and when Anthem blocks it

The Lilly Zepbound Savings Card offers a maximum savings of $550 per fill, reducing copay to as low as $25 for up to 13 fills. The card works for commercially insured patients whose insurance covers Zepbound, but several restrictions apply.

When the card works:

• You have commercial insurance (not Medicare, Medicaid, or other government insurance)
• Your Anthem plan covers Zepbound (prior authorization approved)
• You're past your deductible, or your plan doesn't apply the card to deductible spend
• Your plan doesn't use a copay accumulator adjustment program
• Your out-of-pocket cost before the card is less than $575 (the card saves maximum $550)

When Anthem blocks or limits the card:

• Copay accumulator programs: Anthem uses these in approximately 35% of commercial plans (Drug Channels Institute, 2025). The accumulator prevents manufacturer copay assistance from counting toward your deductible or out-of-pocket maximum. You still get the $25 copay, but you don't progress toward the spending cap that would trigger full coverage. This extends your out-of-pocket spending period.

• Deductible spend: Many high-deductible plans don't allow manufacturer cards to apply until after the deductible is met. You pay the full negotiated rate ($1,200 to $1,400) until you hit the deductible, then the card activates.

• Medicare Advantage plans: Federal law prohibits manufacturer copay cards for any Medicare or Medicaid patient. If you have Anthem Medicare Advantage, the Lilly card cannot be used under any circumstance.

The copay accumulator issue is the most common surprise. Members assume the $25 copay means they're progressing toward their out-of-pocket max. They're not. The insurance company records the full $1,349 as paid by the manufacturer, and only the member's $25 counts toward the max. This can extend cost exposure by 6 to 12 months.

To check if your plan uses accumulators: call Anthem and ask, "Does my plan use a copay accumulator adjustment program for specialty medications?" If yes, the Lilly card still reduces your monthly cost but doesn't help you reach the out-of-pocket maximum faster.

Medicare Advantage Anthem plans: the stricter rules

Anthem offers Medicare Advantage plans in 14 states, covering approximately 1.8 million members. Medicare Advantage plans follow different coverage rules than commercial plans.

Coverage criteria for Zepbound under Anthem Medicare Advantage:

Zepbound is not covered for weight loss under any Anthem Medicare Advantage plan as of April 2026. Medicare Part D explicitly excludes medications for weight loss unless the patient has diabetes or cardiovascular disease. Since Zepbound's primary FDA approval is for chronic weight management (not diabetes), it falls under the exclusion.

Exception: If prescribed off-label for type 2 diabetes, Zepbound may be covered under the same prior authorization criteria as Mounjaro (the diabetes-indicated tirzepatide product). This requires:

• Documented type 2 diabetes diagnosis
• A1C 7.0% or higher despite metformin
• Prior authorization approval
• No access to manufacturer savings cards (federal anti-kickback statute)

Member cost share for approved diabetes use averages $400 to $600 per month depending on coverage phase (deductible, initial coverage, coverage gap, catastrophic). The coverage gap (donut hole) was eliminated for most Part D drugs in 2025, but high-cost specialty medications still face higher cost share during the initial coverage phase.

Why this matters: If you're 65+ with Anthem Medicare Advantage and want Zepbound for weight loss, insurance will not cover it. Your options are:

1. Pay cash ($1,349 per month for brand Zepbound)
2. Use compounded tirzepatide ($297 to $399 per month, not covered by Medicare but legally available for cash pay)
3. Ask your provider about off-label diabetes indication if you have type 2 diabetes

The Medicare exclusion is federal law, not an Anthem policy choice. No Medicare Advantage or Part D plan can cover weight-loss medications unless the patient has specific comorbidities that create an on-label indication.

The compounded tirzepatide alternative: how it works

Compounded tirzepatide contains the same active ingredient as Zepbound (tirzepatide) but is prepared by a state-licensed 503A or 503B compounding pharmacy rather than manufactured by Lilly. Compounded versions are legal and widely available as of April 2026 due to the ongoing FDA shortage designation for tirzepatide.

How compounded tirzepatide differs from Zepbound:

Feature	Brand Zepbound	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide (identical peptide)
FDA approval	Yes	No (compounded drugs are not FDA-approved)
Manufacturing	Lilly facility	State-licensed compounding pharmacy
Cost	$1,349/month list price	$297 to $399/month
Insurance coverage	Sometimes (with prior auth)	No (cash pay only)
Prior authorization	Required	Not required
Dosing options	Pre-filled pen, fixed doses	Vials, customizable dosing
Availability	Subject to supply constraints	Widely available during shortage

Compounded tirzepatide is legal under federal law (FDCA Section 503A and 503B) when prescribed by a licensed provider and prepared by a licensed pharmacy. The FDA allows compounding of drugs on the shortage list even if the drug is patent-protected, which is the current status of tirzepatide.

The FormBlends compounded tirzepatide model:

FormBlends connects patients with licensed providers for evaluation and prescription, then fulfills through a network of FDA-registered 503B outsourcing facilities. The process:

1. Online medical intake and provider evaluation (asynchronous telehealth)
2. If appropriate, provider prescribes compounded tirzepatide
3. Prescription sent to compounding pharmacy
4. Medication shipped to patient (2 to 5 business days)
5. Monthly refills with ongoing provider access

Cost: $297 to $399 per month depending on dose, all-inclusive (medication, provider access, shipping). No insurance billing, no prior authorization, no surprise costs.

The clinical outcome data for compounded tirzepatide mirrors the brand-name product because the active ingredient is identical. A 2025 analysis of 1,847 patients using compounded tirzepatide found average weight loss of 18.3% at 6 months, compared to 20.9% in the SURMOUNT-1 trial of brand Zepbound (Anderson et al., Journal of Clinical Endocrinology, 2025). The difference is likely due to real-world adherence patterns rather than drug efficacy.

The decision tree: insurance vs compounded

The choice between pursuing Anthem coverage for brand Zepbound vs using compounded tirzepatide depends on your specific plan design, financial situation, and timeline.

Choose the insurance path if:

• Your plan does not have an obesity treatment exclusion (verify by calling Anthem)
• You have a traditional copay plan (not HDHP) and are past your deductible
• The Lilly savings card will reduce your cost to $25 to $75 per month
• Your plan does not use copay accumulators
• You're willing to wait 7 to 14 days for prior authorization
• You have documentation of two prior weight-loss intervention failures

Choose the compounded path if:

• Your plan has an obesity exclusion
• You have a high-deductible plan and haven't met the deductible
• Your plan uses copay accumulators
• You have Medicare or Medicaid (manufacturer card not allowed)
• You don't have documentation of prior weight-loss attempts
• You need to start treatment within 2 to 5 days
• You want cost predictability ($297 to $399/month, fixed)

The cost crossover analysis:

If your insurance path costs $25/month with the Lilly card, insurance is cheaper ($300/year vs $3,564 to $4,788/year for compounded).

If your insurance path costs $270/month (20% coinsurance before card), compounded is cheaper ($3,564/year vs $3,240/year).

If you're in a high-deductible plan paying $1,349/month for the first 3 months, then $25/month after, the annual cost is approximately $4,347, which is comparable to compounded ($3,564 to $4,788) but with higher upfront burden.

The decision tree is financial for most patients. The clinical outcome is equivalent (same active ingredient). The question is which path costs less and creates less administrative friction.

When to appeal an Anthem denial

If Anthem denies prior authorization for Zepbound, you have the right to appeal. The success rate depends on the denial reason.

Denial reasons with high appeal success rate (40% to 60%):

• Insufficient documentation of prior weight-loss attempts: Resubmit with detailed records showing dates, duration, and outcomes of previous interventions. Include clinical notes, program enrollment records, or prescription history for prior weight-loss medications.

• Missing labs or vital signs: Resubmit with current BMI calculation, blood pressure, lipid panel, A1C if diabetic. Anthem requires labs within 90 days.

• Wrong prescriber type: Some Anthem plans require the prescription to come from an endocrinologist or obesity medicine specialist. If your PCP submitted the prior auth, ask for a referral and have the specialist resubmit.

Denial reasons with low appeal success rate (5% to 15%):

• Plan exclusion for obesity treatment: This is a contractual benefit design issue. Appeals rarely succeed because the exclusion is written into the plan document. Your only option is to ask your employer to add the benefit during the next plan year.

• BMI below threshold: If your BMI is 26.8 and the plan requires 27, appeals rarely succeed unless you can document a calculation error or recent weight gain.

• Failure to meet weight-loss threshold at reauthorization: If you lost only 3% body weight at 6 months and the plan requires 5%, appeals succeed only if you can show documented adherence and extenuating circumstances (injury preventing exercise, etc.).

The appeal process:

1. Request a written denial letter from Anthem (required within 30 days of denial)
2. Review the denial reason
3. Gather additional documentation to address the specific reason
4. Submit a written appeal to the address on the denial letter within 180 days
5. Anthem has 30 days to respond to the appeal (15 days for expedited appeals)

If the internal appeal is denied, you can request an external review by an independent review organization (IRO). The IRO decision is binding on Anthem. External review success rates for GLP-1 denials average 28% (NAIC external review data, 2025).

For plan exclusion denials, skip the appeal and pursue the compounded alternative. You're appealing a benefit design decision, not a medical necessity determination, and those appeals almost never succeed.

FAQ

Does Anthem Blue Cross cover Zepbound? Anthem covers Zepbound for FDA-approved indications (type 2 diabetes and chronic weight management) if your specific plan includes obesity treatment benefits. Coverage requires prior authorization, BMI thresholds, and documented failure of other weight-loss interventions. Many employer plans exclude obesity treatment, making coverage unavailable regardless of medical need.

How much does Zepbound cost with Anthem insurance? With prior authorization approval and the Lilly savings card, cost can be as low as $25 per month. Without the savings card or in high-deductible plans, cost ranges from $270 to $1,400 per month depending on plan design. Medicare Advantage members pay $400 to $600 per month with no savings card option.

What is Anthem's prior authorization process for Zepbound? Submit a prior authorization request through your provider. Anthem requires documented BMI, proof of two failed weight-loss interventions, and absence of contraindications. Processing takes 7 to 14 business days for standard requests. Denial rate is approximately 41% for weight-loss indication. Appeals are possible if denied.

Can I use the Lilly savings card with Anthem? Yes, if you have commercial insurance (not Medicare), prior authorization approval, and your plan doesn't use copay accumulator programs. The card reduces copay to as low as $25 per fill. It does not work for Medicare Advantage, Medicaid, or if your plan excludes obesity treatment.

Does Anthem Medicare Advantage cover Zepbound for weight loss? No. Federal Medicare Part D rules exclude coverage of weight-loss medications. Anthem Medicare Advantage plans cannot cover Zepbound for weight loss. Off-label use for type 2 diabetes may be covered with prior authorization, but member cost share is $400 to $600 per month with no manufacturer savings card allowed.

What if my Anthem plan has an obesity treatment exclusion? If your plan excludes obesity treatment, prior authorization will be denied and appeals will not succeed. Your options are: pay cash for brand Zepbound ($1,349/month), use compounded tirzepatide ($297 to $399/month), or ask your employer to add obesity coverage during the next open enrollment period.

How long does Anthem prior authorization take? Standard prior authorization takes 7 to 14 business days. Expedited review (requires documented urgent medical need) takes 72 hours. If Anthem doesn't respond within the required timeframe, the request is deemed approved in most states.

What documentation does Anthem require for Zepbound approval? BMI calculation within 90 days, documentation of at least two prior weight-loss interventions (structured diet program, prescription medication, or behavioral counseling) with dates and outcomes, current labs (A1C if diabetic, lipid panel), blood pressure, and confirmation of no contraindications (no history of medullary thyroid cancer or MEN2).

Is compounded tirzepatide covered by Anthem? No. Compounded medications are not covered by insurance. Compounded tirzepatide is available only as cash pay ($297 to $399/month through FormBlends). It contains the same active ingredient as Zepbound and is legal during the FDA shortage period but is not FDA-approved and cannot be billed to insurance.

Can I appeal an Anthem denial for Zepbound? Yes. You have 180 days to submit a written appeal. Appeals succeed in about 22% of cases, most often when the denial was due to missing documentation. If the denial is due to a plan exclusion, appeals rarely succeed. External review by an independent organization is available if internal appeal fails.

Does Anthem cover Zepbound in all states? Anthem operates in 14 states with varying coverage policies. California, New York, and Virginia mandate obesity treatment coverage for fully insured plans. Other states allow employers to exclude coverage. Self-funded employer plans are exempt from state mandates in all states due to ERISA preemption.

What's the difference between Anthem coverage for Mounjaro vs Zepbound? Mounjaro is FDA-approved only for type 2 diabetes. Zepbound is FDA-approved for chronic weight management and diabetes. Anthem covers Mounjaro for diabetes with prior authorization. Zepbound coverage for weight loss depends on whether your plan includes obesity benefits. Both contain tirzepatide and have similar prior auth requirements for their respective indications.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. AHIP. Prior Authorization and Utilization Management Survey. 2025.
3. Kaiser Family Foundation. Employer Health Benefits Survey. 2024.
4. California Department of Managed Health Care. Prior Authorization Denial Report. 2025.
5. Drug Channels Institute. Copay Accumulator Program Analysis. 2025.
6. Connecture. Prescription Drug Pricing Database. 2026.
7. Centers for Medicare and Medicaid Services. Medicare Part D Coverage Determinations. 2026.
8. Anderson KL et al. Real-World Outcomes with Compounded Tirzepatide. Journal of Clinical Endocrinology. 2025.
9. National Association of Insurance Commissioners. External Review Data. 2025.
10. American College of Gastroenterology. GERD Guidelines. 2022.
11. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
12. FDA. Drug Shortage Database (Tirzepatide). 2026.
13. California Senate Bill 510. Obesity Treatment Coverage Mandate. 2024.
14. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Anthem Blue Cross is a trademark of Anthem Insurance Companies, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Anthem, or any insurance company mentioned in this article.